La nueva "normalidad" en México
Keywords:
Coronavirus, Mexico, EpidemiologyAbstract
Starting on June 01, a new phase began in Mexico that has been called by the Mexican Health Secretariat as the "New Normality",by terminating the phase called "Day of Healthy Distance" started on 23 March and ended on May 31, in which one of the main tools to
reduce the number of contagion was keeping most of the population at home, those who did not have an activity that was not considered
essential, there being some states of the Mexican Republic that to the best of their ability complied with this provision, as far as
possible because in reality 10,167 deaths and 93,435 cases (Tests carried out 282,089)
Downloads
References
Aragón-Nogales R, Vargas-Almanza I, Miranda-Novales MG. COVID-19 por SARS-CoV-2: la nueva emergencia de salud. Rev. Mex Pediatr. 2019; 86(6): 213-218. doi:10.35366/91871.
Gobierno de México (2020). Coronavirus 19. Disponible en: https://coronavirus.gob.mx/datos/
Instituto Mexicano del Seguro Social (IMSS) (2020) Coronavirus (COVID-19) Disponible en: http://www.imss.gob.mx/covid-19
Dirección General de Epidemiología. Lineamiento estandarizado para la vigilancia epidemiológica y por laboratorio de enfermedad por 2019-nCoV. México: Secretaría de Salud, 2020 [citado febrero 15, 2020]. Disponible en: https://www.gob.mx/cms/uploads/attachment/file/532752/Lineamiento_2019_nCoV_2020_02_07.pdf
Cabrera-Gaytán DA, Vargas-Valerio A, Grajales-Muñiz C. Infección del nuevo coronavirus: nuevos retos, nuevos legados Revista Médica del Instituto Mexicano del Seguro Social 2014; 52 (4): 438- 441
Paules CI, Marston HD, Fauci AS. Coronavirus-More than just the common cold (Opinion). JAMA. 2020. https://doi.org/10.1001/jama.2020.0757
Urbiztondo L, Borras E, Mirada G. Vacunas contra el coronavirus. Vacunas 2020; 21(1): 69-72.https://doi.org/10.1016/j.vacun.2020.04.002
Inovio Accelerates Timeline for COVID-19 DNA Vaccine INO-4800. Disponible en: http://ir.inovio.com/news-andmedia/news/press-release-details/2020/Inovio-Accelerates-Timeline-for-COVID-19-DNA-Vaccine-INO-4800/default.aspx
Organización Mundial de la Salud (OMS) (2020) Disponible en: https://www.who.int/es/emergencies/diseases/novel-coronavirus-2019/advice-for-public/q-a-coronaviruses?gclid=CjwKCAjwm_P5BRAhEiwAwRzSOxy4U7TnwwF--2GqSd3zi-KtLOFJJGvY7wibESb7VmrFOHHKTefBshoCSHsQAvD_BwE
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2020 Escuela de Salud Pública y Ambiente. Facultad de Ciencias Médicas. Universidad Nacional de Córdoba
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License which allows the work to be copied, distributed, exhibited and interpreted as long as it is not done for commercial purposes.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) after the publication process. (See The Effect of Open Access). (See The Effect of Open Access).
